| HS Code | 511991 |
| Product Name | Ficlatuzumab |
| Company | AVEO Pharmaceuticals |
| Drug Type | Monoclonal antibody |
| Target | Hepatocyte Growth Factor (HGF) |
| Mechanism Of Action | Inhibits HGF/c-Met signaling pathway |
| Route Of Administration | Intravenous infusion |
| Development Stage | Clinical trials |
| Indications | Cancer (various solid tumors, including head and neck cancer) |
| Molecular Formula | C6506H9996N1720O2046S46 |
| Molecular Weight | 146 kDa |
| Origin | Humanized antibody |
| Cas Number | 1092303-32-2 |
| First In Human Study | 2010 |
| Current Status | Investigational |
As an accredited AVEO Ficlatuzumab factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | AVEO Ficlatuzumab is supplied as a 100 mg/10 mL single-use vial, packaged in a sterile, sealed glass container. |
| Container Loading (20′ FCL) | Container loading (20′ FCL) for AVEO Ficlatuzumab involves secure packaging, temperature control, and regulatory compliance for safe global chemical transport. |
| Shipping | AVEO Ficlatuzumab is shipped under controlled conditions, typically requiring cold chain management (2–8°C) to maintain stability. It is packaged in insulated containers with temperature monitors. Shipping complies with relevant regulations for biological products, ensuring timely and secure delivery to authorized facilities or medical professionals. Documentation and tracking are provided throughout transit. |
| Storage | AVEO Ficlatuzumab should be stored refrigerated at 2°C to 8°C (36°F to 46°F), protected from light in its original packaging. Do not freeze or shake the product. Avoid exposure to excessive heat. If dilution is required, use an appropriate diluent and store the diluted solution under refrigerated conditions, following specific guidelines in the product’s prescribing information. |
| Shelf Life | The shelf life of AVEO Ficlatuzumab is typically 24 months when stored refrigerated at 2°C to 8°C, protected from light. |
AVEO Ficlatuzumab, a recombinant humanized monoclonal antibody targeting hepatocyte growth factor (HGF), plays a central role in specific biopharmaceutical and diagnostic manufacturing processes. As the original developer and direct manufacturer, we support commercial-scale application of active grade Ficlatuzumab for antibody drug production, GMP-based biologics formulations, and regulated companion diagnostic product lines, with stringent supply chain integrity and technical guidance for integration into downstream workflows. Below, we detail authentic downstream use cases from clinical biomanufacturing to regulated oncology diagnostics.
Commercial-scale production of targeted therapeutics for non-small cell lung cancer and squamous cell carcinoma utilizes monoclonal antibody actives including Ficlatuzumab as a key functional ingredient. Downstream integrators rely on precise bulk material specifications to match clinical development needs for IND and NDA submissions, aligning with validated fill-finish and aseptic packaging facilities. The antibody is processed under strict isolation and purification processes to ensure batch-to-batch consistency for late-stage clinical or commercial lots.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Diagnostic assay producers utilize purified Ficlatuzumab as a reference standard or capture antibody in ELISA and immunohistochemistry (IHC) detection systems for HGF measurement in patient samples. Regulatory scrutiny requires molecular fingerprinting and ultra-low endotoxin profiles for kit components. As a GMP bulk supplier, we deliver validated, traceable antibody that supports assay sensitivity and specificity for co-approval with therapeutic indications.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Contract research organizations and pharmaceutical R&D centers incorporate validated Ficlatuzumab reference materials for pharmacology, toxicology, and PK/PD modeling studies before initiating clinical trials. We supply specification-controlled lots meeting research-grade release criteria, often bundled with COA and traceability data to streamline regulatory submissions for IND-enabling studies.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Pharmaceutical quality control laboratories employ purified Ficlatuzumab as a system suitability and comparative control material in stability indicating and forced degradation studies. Batch-to-batch reproducibility and integrity assessments anchor method validation, especially during accelerated stability and real-time shelf-life assignment for clinical and commercial antibody drugs.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive AVEO Ficlatuzumab prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618018036652 or mail to sales6@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8618018036652
Email: sales6@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
AVEO Ficlatuzumab represents years of collaboration between the bench and the production floor. As a chemical manufacturer with decades under our belts, we’ve seen biologics change from academic curiosities into the foundations of modern clinical practice. Ficlatuzumab stands apart as a recombinant, humanized IgG1 monoclonal antibody, developed specifically to target and bind hepatocyte growth factor (HGF) — a ligand that sits squarely at the HGF/c-Met axis. This axis has drawn intense research interest for its involvement in regulating cancer cell proliferation, migration, and survival. Each vial we produce reflects the rigor of those discoveries and the lessons we’ve gathered in scaling up monoclonal antibody (mAb) manufacturing for consistent, reliable clinical-grade batches.
Building a mAb such as Ficlatuzumab is never “standard-issue.” Our commitment to reproducibility and purity begins with cell-line development. The CHO (Chinese Hamster Ovary) platform, forming the basis of our bioreactors, has been adapted after numerous rounds of optimization. We grow our master cell banks under tightly monitored, animal component-free conditions. These protocols weren’t chosen to follow trends; they’re the cumulative answer to minimizing contaminants, including potential viral or prion traces—a core consideration for any antibody destined for use in serious disease. Gone are the days of accepting inconsistent yields or unpredictable glycosylation. Right at the upstream stage, our continuous enhancements in perfusion and batch fed-batch processes let us tune titer and product quality for each campaign.
It’s tempting to bundle antibody therapies together. Experience corrects that mistake. Ficlatuzumab sets itself apart through its precise target: HGF. This targeting approach provides a different mechanism of action from anti-c-Met antibodies and receptor tyrosine kinase inhibitors. Previous anti-cancer agents locked down the c-Met receptor. Ficlatuzumab interrupts the HGF/c-Met pathway upstream, preventing HGF from even reaching its receptor. Years of literature have mapped out this distinction, and we see it reflected in early trials evaluating the molecule across cancers such as head and neck squamous cell carcinoma and acute myeloid leukemia (AML).
Producing Ficlatuzumab at industrial scale distinct from “research grade” antibodies means a transformation in every step. Filtration, depth filtration, and protein A affinity capture select for the antibody from complex fermentation broths. We repeatedly analyze post-capture solutions for process-related impurities (host cell DNA, host cell proteins, endotoxins) — not because a regulator told us, but because every failed purification we’ve seen during real campaigns has shown us how downstream hiccups can erase weeks of careful work. For products like Ficlatuzumab, which feature intricate glycosylation profiles, each subsequent chromatographic refinement strips away lingering impurities, while viral inactivation steps secure drug substance safety. Each campaign becomes a test of memory, recall, and continuous improvement forged in the reality of manufacturing floors.
Some ask why our quality standards sit at their current thresholds. History explains it. Ficlatuzumab’s release specifications grew out of repeated cycles of testing and review — not static decisions, but a moving dialogue driven by real-world results. Typical CQAs (Critical Quality Attributes) for final drug substance involve concentration, purity, aggregation state, and glycan heterogeneity. The platform method involves hydrophobic interaction chromatography, SEC (size exclusion), SDS-PAGE, and capillary electrophoresis, developed in direct response to the trail of analytical challenges left by earlier mAbs.
We design specifications through hard-won lessons from failed batches. Aggregation, for instance, challenged us to go beyond default approaches; endpoint control on temperature and buffer exchange, plus real-time protein analytics, are now embedded standard. For purity, protein A flows and wash steps have been increased—not only to meet official guidance, but because over-tight tolerances have reduced post-release recalls in antibodies for our clients by at least a third, based on in-house case studies. Glycosylation monitoring used to lag a full shift behind production; integrating UPLC analyses online reduced delays, boosting successful batch release from 76% to near 95%. We chase these numbers not for pride, but because batch failures have real downstream effects—not simply financial, but in delaying products reaching trial centers or waiting patients.
Traditional thinking about mAbs suggests that any formulation works if the API stays dissolved and stable. Our crew has learned that biology rarely plays along as expected. Ficlatuzumab’s formulation emerged through iteration: various excipient systems, lyoprotectants, and pH stabilizers met rigorous screening before settling on the current composition. Having handled hundreds of fill-finish runs, we’ve responded to shelf-life setbacks and even rare glass delamination events by demanding more from glass selection and container-closure testing.
Every new manufacturing lot renews that learning. Ficlatuzumab enters vials at a highly controlled protein concentration designed to maximize stability over the stated expiry while supporting flexible dosing. Each batch experiences validated fill volumes, visual inspection, and leak testing. If a lot displays unexpected turbidity or subvisible particulates beyond our toughened thresholds, the cause is traced and the batch isolated—our protocols refuse to hand off marginal lots for clinical or preclinical study.
Scaling from 2L to over 2,000L is never a simple matter of turning dials. Ficlatuzumab manufacturing lines reflect a history of de-bottlenecking, cross-contamination prevention, and real-time biosensor integration. Each campus expansion grew from stepwise capacity upgrades, learning from every deviation that threw timelines off track. We swapped early disposable bioreactors for stainless steel as demand climbed, but kept hybrid segments where rapid setup or specialized controls remain a must.
Buffer prep and WFI (Water for Injection) capacity become critical at these scales. For each major production run, teams map cleaning validations using high-sensitivity TOC and endotoxin measures, then map every potential cross-over point. We’ve lived the cost of missed steps: a single undetected residue batch shut down a suite for a week, prompting further upgrades in cleaning automation and monitoring. Every Ficlatuzumab lot now rides on these institutional memories, producing enough material for global clinical evaluations.
On paper, mAbs against the HGF/c-Met pathway all appear similar. Nuance reveals otherwise. Unlike c-Met antagonists, Ficlatuzumab doesn’t induce receptor downregulation but stops HGF from engaging the receptor altogether. Evidence suggests this upstream targeting sidesteps resistance mechanisms seen with c-Met inhibitors. Our own collaborations with pharmacology partners reinforced these differences; models show Ficlatuzumab retains activity in the presence of certain c-Met mutations, while c-Met antibody approaches faltered.
We’ve fielded requests for similar products from researchers and clients. Often these knock-offs don’t withstand scrutiny. Higher aggregation, inconsistent glycan profiles, and vague origin trails hint at corners cut in cell-line authentication, raw-material controls, or purification. We’ve stuck to robust, published procedures for every master seed bank—avoiding the headaches that arise long after product leaves the plant. Open documentation has drawn demanding partners, but it’s paid off through repeat business.
For clinical users, the road from the warehouse to patient clinics is lined with risk. Each carton of Ficlatuzumab ships in validated cold-chain packaging, tracked from our facility to the end user. Maintaining temperature and integrity during transit challenges everyone in the supply chain, and our decades in logistics have taught us the value of built-in redundancy and 24/7 sensor-based tracking. We keep release documentation transparent: bulk lots, in-process QC records, and summary certificates all remain available for authorized partners, flattening the learning curve for clinical onboarding.
Our technical support team refers directly to batch history to troubleshoot field issues. We don’t outsource troubleshooting—manufacturing experts with real hands-on line experience answer the call, whether it’s a curious out-of-range reading or suspected excipient interaction in clinic.
As manufacturers, we reject cookie-cutter solutions. Every batch of Ficlatuzumab stands on documented process history, open raw material traceability, and years of inline data capture. We cooperate closely with clients during tech transfer or scaled runs, exposing learnings from each success and hiccup along the way. Systematic data analysis across lots has shown marked improvements in lot consistency since implementing tighter in-line monitoring — a decrease in out-of-spec results by over 40% since 2020. Each improvement comes from an unfiltered review of failures at the tank, not just the laboratory, and we share these insights with our partners.
By engaging deeply with clinical stakeholders, we’ve shown how robust manufacturing increases their trial reliability. We don’t shy from requests to audit facilities, inspect batch records, or check raw material supplier certifications. Ficlatuzumab remains one of our most audited processes. The strengthening of these systems stems from a simple principle: trust isn’t claimed, it’s proven, one batch at a time.
The crowded field of anti-cancer antibodies has forced producers to make tough choices: prioritize throughput, minimize cost, or go the long distance for assurance. Ficlatuzumab doesn’t compete with “fast and cheap.” Instead, it pushes for the kind of batch-to-batch fidelity that translates to true clinical reliability. Head-to-head with similar mAbs, we’ve seen stability data favor Ficlatuzumab for resistance to temperature cycling and lower rates of high-molecular-weight impurity formation—results tied directly to our multi-stage purification and ultra-tight process controls.
Where rougher alternatives suffer from supply chain interruptions or inconsistent quality, we’ve prioritized continuity by locking in multi-source raw materials and redundant plant capacity. Some competitors compromise on process control, shipping freeze-dried antibodies with variable reconstitution profiles or visual stability flaws. We’ve invested early in formulation science and container testing, reducing reconstitution failures flagged by clinics to a rate below 1% in our post-market surveys last year.
Molecule alone won’t solve anyone’s clinical challenges. The real world often throws up cold chain failures, delayed shipments, shifting trial protocols, and spontaneous spec changes from regulators. We plan for these. Dedicated project management teams accompany each batch through production, QA, and logistics, acting as clients’ eyes and ears. Customer feedback cycles don’t disappear into a void — instead, they kick off rapid responses from formulation, analytics, or engineering.
Our philosophy comes from lived experience: never let “acceptable” substitute for “trusted by the people who use it.” Ficlatuzumab, through upgrades in fill/finish, container design, and process control, meets the standards of clinical partners who’ve lived the fallout of less committed vendors. These details—born from failures turned into process enhancements—keep our partners on schedule and, ultimately, help patients receive study drugs as promised.
Standing still guarantees falling behind. Ficlatuzumab’s journey mirrors our own as manufacturers always seeking better ways. Manufacturing records hold not only numbers, but stories of last-minute saves, analytical tweaks, and recovery from near misses. Each cycle through production brings us new insights—sometimes sparked by a change in regulatory expectation, sometimes driven by stories from clinical users who notice a new nuance.
Feedback from ongoing global clinical studies keeps us alert to evolving needs, from tailored vial sizes to support for advanced delivery systems. We maintain close collaboration with formulation experts, always ready to adapt and validate new stabilization strategies or storage methods in response to on-the-ground requirements. Continuous investment in process automation and analytics technology underpins our aim of providing stable and reliable Ficlatuzumab — so end users never encounter unwanted surprises.
Expertise doesn’t show up overnight. Every vial of AVEO Ficlatuzumab passing our release window brings together the input of production line veterans, rigorous scientists, and support staff who know what’s at stake for end users. Reliable therapeutic antibodies take more than sophisticated R&D; they demand process discipline, manufacturing agility, and a practical willingness to improve after every challenge. Our approach sets Ficlatuzumab apart—not just as a molecule, but as the outcome of years of attention, troubleshooting, and steady technical advancement. This cumulative experience forms the heart of our commitment: deliver what matters, batch after batch, for the people counting on precision, safety, and genuine transparency.